Relationship between MGMT and Tiam1 Expression in Patients with Brain Metastases from NSCLC Treated with Concurrent Intensity-modulated Radiotherapy Combined with Temozolomide
CHAI Lixia, WANG Rong, YANG Shirong, et al
The Fifth People's Hospital of Qinghai,Xining Qinghai 810000,China
Abstract：Objective: To analyze the relationship between the efficacy of concurrent radiotherapy combined with temozolomide and the expression of O6 methylguanine DNA methyltransferase (Mgmt) and invasion and metastasis inducing factor 1 (Tiam1) in patients with brain metastases from non-small cell lung cancer (NSCLS).Methods: 60 NSCLC patients with brain metastasis were treated with simultaneous modulated accelerated radiotherapy and temozolomide,which of the expression of MGMT and Tiam1 in lung tissue was detected by immunohistochemistry and the relationship between the expression of MGMT and Tiam1 and the therapeutic effect and the survival time were analyzed.Results: The relief rate (RR) of 21 patients with MGMT (+) and Tiam1 (+) was 76.19%,the disease control rate (DCR) of which was 95.23%;The RR of 16 patients with MGMT (+) and Tiam1 (-) were 25.00%,the DCR of which was 81.25%;The RR of 17 patients with MGMT (-) and Tiam1 (-) were 88.24%,the DCR of which was 94.12%;The RR of 6 patients with MGMT (-) and Tiam1 (-) were 33.33%,and the DCR of which was 66.6% 7%.The follow-up time of 60 patients ranged from 1 to 45.35 months,the median follow-up time was 16.75 months and the median survival time was 13 months,where the 1-year,2-year and 3-year survival rates were 75.01%,53.86% and 25.31%,respectively.The median survival time of 21 patients with MGMT (+) and Tiam1 (+) was 13 months,where the 1-year,2-year and 3-year survival rates were 64.32%,45.15% and 20.33%,respectively.The median survival time of 16 patients with MGMT (+) and Tiam1 (-) was 6 months,where the 1-year,2-year and 3-year survival rates were 33.69%,20.01% and 0.00%,respectively.The median survival time of 17 patients with MGMT (-) and Tiam1 (+) was 15 months,where the 1-year,2-year and 3-year survival rates were 92.05%,74.12% and 40.09%,respectively.The median survival time of 6 patients with MGMT (-) and Tiam1 (-) was 10 months,where the 1-year,2-year and 3-year survival rates were 55.63%,47.35% and 18.96%,respectively.Conclusion: The different expression of MGMT and Tiam1 in lung cancer is related to the therapeutic effect of simultaneous modulated accelerated radiotherapy combined with temozolomide on NSCLS patients with brain metastasis.
柴丽霞, 王嵘, 杨世荣, 马莉莎, 华毛, 韩国雄, 荀森. 同步加量调强放疗联合替莫唑胺对非小细胞肺癌脑转移的治疗效果与MGMT和Tiam1表达的关系[J]. 河北医学, 2020, 26(11): 1814-1818.
CHAI Lixia, WANG Rong, YANG Shirong, et al. Relationship between MGMT and Tiam1 Expression in Patients with Brain Metastases from NSCLC Treated with Concurrent Intensity-modulated Radiotherapy Combined with Temozolomide. HeBei Med, 2020, 26(11): 1814-1818.
2020, Vol. 26 
冀公网安备13080202000677号